Researchers have demonstrated that the enzymatic activity of R5 receptor-type protein tyrosine phosphatases is a requisite for the maintenance of stem cell properties and tumorigenicity in glioblastoma cells and could be a promising drug target for treatment.
In a new study published in Scientific Reports, the investigators also reported a higher risk of glioblastoma in Alzheimer’s patients.
This review explores commonly used experimental models of GBM, recent improvements to these models and strategies for developing advanced models.
A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.
Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
The article reviews current literature on the use of adoptive immunotherapy for malignant gliomas as well as the
the concept of antitumor activity mediated by CIK cells.
A large, multicenter, genome-wide association study has identified a number of new genetic risk loci for malignant brain tumors.
Researchers have identified novel genetic errors associated with an increased risk of developing glioma, in the largest ever study of the disease.
Immunotherapy for glioblastoma has been an area of intense research in recent years – this review looks at the potential of HCMV in the initiation, promotion and progression of tumorigenesis.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.
Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.